Database release

2020-12-03 Categories: Database, Release

Added entries:

(FDA) RET somatic variants associated with sensitivity to pralsetinib in advanced or metastatic medullary thyroid cancer.
(FDA) RET fusions associated with sensitivity to pralsetinib in advanced or metastatic thyroid cancer.
(Inferential) CDK274 amplifications associated with sensitivity to chemotherapy in combination with pembrolizumab in locally recurrent or metastatic triple-negative breast cancer.

Edited entries:

(Guideline) CDK4 amplifications associated with sensitivity to palbociclib in well-differentiated and dedifferentiated liposarcoma, updated source.
(Guideline) KIT somatic variants associated with sensitivity to sunitinib in thymic carcinomas, updated source.

Removed entries:

(Preclinical) CDKN2B deletions associated with sensitivity to EPZ015666.